Why 2026 Is the Year Canadian Benefits Plans Have to Get Serious About Weight-Loss Drugs

There is no drug class reshaping Canadian benefits plans faster than GLP-1s. Ozempic, Wegovy, Mounjaro and Zepbound have moved from diabetes management into mainstream weight-loss and, increasingly, cardiovascular care. They are now the single biggest force pulling on plan budgets, plan design and plan-sponsor strategy. In just the past few weeks, a cluster of developments has changed the calculus for employers again.

Here’s what’s changed, and what it means for your plan.

1. Ozempic Just Got Cheaper for Individuals With Private Plans

On July 6, 2026, Novo Nordisk Canada expanded its Ozempic Savings Card to eligible Canadians with private drug coverage – not just those paying entirely out of pocket. Under the expanded program, plan members can buy brand-name semaglutide at a price the company says is aligned with generic alternatives, with the discount applied automatically at pharmacies nationwide (Quebec excluded) through Novo Nordisk Care Rx (operated by Rexall) and select telehealth and retail partners.

• Why it matters for plan sponsors: This is a direct response to the wave of generic semaglutide now entering the Canadian market. Manufacturer savings cards can reduce out-of-pocket costs for members, but they also influence which product gets dispensed – which can work against a plan’s generic-substitution and cost-containment strategy. Plan sponsors and advisors should understand how these cards interact with their mandatory-generic and tiering rules, because “free to the member” is rarely free to the plan.

2. Canada Is Now the Generics Testing Ground For the World

Canada has become the first G7 country to approve generic semaglutide. Health Canada authorized its first generic version of Ozempic (Dr. Reddy’s Laboratories) on April 28, 2026, followed days later by a second (Apotex), and has since approved the first generic version of Wegovy for weight loss (Apotex’s “Sevmia”). Roughly seven to nine additional generic submissions remain under Health Canada review.

Generics in Canada typically run 45% to 90% cheaper than brand, and analysts expect plan sponsors to begin seeing meaningful savings on semaglutide through mid-to-late 2026, with near-term reductions of 30% to 50% viewed as realistic.

• Why It Matters: After two years of GLP-1s being a runaway cost line, this is finally some good news for plan budgets – but only for plans positioned to capture it. Generic substitution rules, formulary tiering and prior-authorization criteria all need to be current, or the savings leak away.

3. The Tirzepatide Drugs (Mounjaro/Zepbound) Aren’t Following Yet

Not all GLP-1s are about to become affordable. The more potent dual-action drugs, Mounjaro and Zepbound (tirzepatide), are on a very different timeline. While the U.S. FDA has agreed to review generic Tirzepatide applications (from Sandoz), Eli Lilly holds patent protection in the U.S. until 2036. A true generic Tirzepatide is unlikely for another decade.

• Why It Matters: As prescriptions migrate patients toward Tirzepatide (often more effective for weight loss), plans could see utilization shift toward the drugs that will stay brand-priced and expensive for another decade – partially offsetting the savings from cheaper semaglutide. Coverage design should account for this substitution effect, not just today’s drug mix.

4. The Cost Pressure Is Real and No Longer Just a Diabetes Story

The numbers explain the urgency. Ozempic alone accounts for roughly $807 million of public drug plan spending and was responsible for 8.5 of the 9.2 percentage points of one recent annual increase in public drug spend. On the private side, GLP-1s remain a top driver of employer drug-plan cost growth, and future approvals, for conditions like sleep apnea and metabolic liver disease (MASH), will only widen the eligible population.

Most Canadian employer plans now offer some GLP-1 coverage, but tightly managed: coverage is common for diabetes, far less common for weight loss, and where weight-loss coverage exists it usually carries prior authorization, BMI thresholds, step therapy, and annual or lifetime maximums.

5. The Hardest Question: A New Cardiovascular Study Challenges the “Cap and Cut Off” Model

This is the development that should give every plan sponsor pause. New research (using U.S. Veterans Affairs data) found that adults with type 2 diabetes who stayed on GLP-1s continuously saw an 18% reduction in cardiovascular risk versus older drugs, but the protection erodes when treatment stops. Stopping for as little as six months raised risk by ~4%, and two years off treatment raised risk by ~22%.

• The Issue This Creates: many plans that cover obesity do so with a maximum that funds only three to six months of therapy. That design can now produce the worst-case outcome: a member achieves rapid health gains, hits the cap, loses coverage, and then faces both weight regain and elevated cardiovascular risk from stopping. Meanwhile, 72% of employers cite high discontinuation and weight regain as reasons not to cover GLP-1s – and among large employers, the posture has shifted from cautious expansion to cautious contraction.
• Why It Matters: The cardiovascular evidence reframes GLP-1s as potentially chronic, ongoing therapy rather than a short-term weight-loss course. That collides directly with the short-duration caps most plans use to control cost. Plan sponsors can no longer treat coverage as a simple yes/no; they need a defensible clinical and financial philosophy.

6. Pharmacy Savings Cards Are Already Reducing GLP-1 Costs for Members

Manufacturer cards aren’t the only programs lowering what Canadians pay at the pharmacy counter. Free prescription savings cards, funded by pharmaceutical manufacturers, already cover brand-name GLP-1s and work alongside existing drug plans.

innoviCares: The most established is innoviCares, a free card that has helped more than 5.5 million Canadians save on brand-name prescriptions. Presented at the pharmacy, the card pays a portion of the cost of participating brand-name medications and coordinates as secondary coverage, meaning it applies after a member’s private or public plan. Its current coverage list (March 4, 2026) includes both Ozempic and Wegovy (semaglutide injection), with benefits available in every province and territory except Quebec. The pharmacy keeps the card information on the member’s profile, so savings apply automatically to future fills, and new medications are added to the program regularly.

RxHelp ONE: A similar card program, RxHelp ONE connects Canadians to manufacturer patient-assistance pricing on a long list of brand-name medications. Its Ontario medication list (March 4, 2026) does not yet include any GLP-1s, a useful reminder that coverage varies by program and province and changes as products are added.

• Why It Matters: These cards cost members nothing and can meaningfully cut out-of-pocket spending on semaglutide, especially for members with coinsurance, annual caps or no weight-loss coverage at all. For plan sponsors, the caution from Section 1 applies here too: because these programs pay only on brand-name products, they encourage brand dispensing just as cheaper generic semaglutide arrives, and they can interact with mandatory-generic rules in ways that shift cost back to the plan. Members should know these programs exist; sponsors should know how they coordinate with the plan.

What This Means for Employers and Plan Sponsors

The era of treating GLP-1s as a niche exclusion is over. The right response isn’t blanket coverage or blanket denial – it’s a deliberate strategy.

We’re advising plan sponsors to:

• Define a philosophy first. Decide whether GLP-1s are a core part of your chronic-disease support or a limited, budgeted add-on. Every design decision flows from that.
• Revisit maximums in light of the cardiovascular data. Short-duration caps may be creating clinical and liability risk, not just saving money. Consider outcome-based or continuation criteria over hard three-to-six-month cutoffs. Position to capture generic savings. Ensure generic-substitution rules, tiering and prior-authorization criteria are current so semaglutide savings actually reach the plan.
• Plan for the Tirzepatide gap. Model what happens to your costs if utilization shifts to Mounjaro/Zepbound, which won’t have generics for years.
• Understand manufacturer savings cards. Know how programs like the expanded Ozempic Savings Card interact with your cost-containment rules – they can help members but complicate plan strategy.
• Use prior authorization and clinical criteria, not just dollar caps. Well-designed clinical gating manages cost while avoiding the abrupt-discontinuation trap.

The plans that win in 2026 won’t be the ones that simply spend the least on GLP-1s – they’ll be the ones that spend deliberately, capturing generic savings while designing coverage that improves the health outcomes they’re paying for.

Sources:

1. Benefits and Pensions Monitor: Novo Nordisk opens Ozempic savings card to Canadians with private drug plans
2. IFEBP Word on Benefits: GLP-1 Drug Coverage Continues to Rise in Canada
3. Healthline: Mounjaro, Zepbound: Generic GLP-1 Drugs May Soon Be Available
4. Canadian HR Reporter: New GLP-1 cardiovascular study raises tough questions for Canadian group benefits plans
5. Insurance Business Canada: GLP-1 cost surge puts pressure on Canadian drug plans: report.
6. Health Canada: Canada approves first generic semaglutide (G7 first)
7. Benefits Canada: Expanded use of GLP-1s a major driver of drug plan costs in 2026.
8. innoviCares: What’s Covered, Canada-wide medication list (March 4, 2026)
9. innoviCares: Patient savings card, multi-use benefit (May 19, 2026)
10. RxHelp ONE: Medications available for Ontario (March 4, 2026)